A higher incidence of smooth endoplasmic reticulum clusters with aromatase inhibitors. (11th September 2019)

• Record Type: Journal Article
• Authors: Saito, Hiroe; Otsuki, Junko; Takahashi, Hiromi; Hirata, Rei; Habara, Toshihiro; Hayashi, Nobuyoshi
• Is Part Of: Reproductive medicine and biology. Volume 18:Number 4(2019)
• Page Start: 384
• Page End: 389
• Publication Date: 2019-09-11
• Subjects: aromatase inhibitor -- clomiphene citrate -- estradiol -- progesterone -- smooth endoplasmic reticulum; Reproduction -- Periodicals; Reproductive health -- Periodicals; 612.6
• DOI: 10.1002/rmb2.12296
• Languages: English
• ISSNs: 1445-5781

Abstract

Abstract: Purpose: This study aimed to analyze whether a regimen of aromatase inhibitor (AI) could reduce the occurrence of smooth endoplasmic reticulum clusters (sERCs) in oocytes. Method(s): The AI and the clomiphene citrate (CC) regimens were compared, regarding the sERC (+) rates and the serum estradiol and progesterone levels on the date of hCG administration, and the duration of AI, CC, and hMG administration. Result(s): The occurrence of sERCs in oocytes from patients treated with AI was significantly higher than that in oocytes from those treated with CC. Both the serum estradiol and progesterone levels were found to be significantly higher in sERC (+) than in sERC (‐) cycles. With regard to the CC cycles, no significant differences were detected. The duration of AI and hMG administration was longer for sERC (+) than for sERC (‐) cycles. Conclusion: As AI did not reduce the occurrence of sERCs, the elevation of estradiol may not be the cause of sERC occurrence but a consequence. Considering the higher levels of progesterone and longer duration of hMG in sERC (+) cycles, the negative effects of premature luteinization, which frequently occur with the AI protocol, should be investigated further.